Sildenafil and Riociguat: Why FDA Lists It as Contraindicated
FDA sildenafil labeling contraindicates concomitant riociguat use due to hypotension risk. See the exact label language and every related revision from 2020 to 2026.
Viagra Sildenafil: Regulatory History
7 source-based articles maintained by the HealthRX.com Editorial Team.
7articles
4topic areas covered
May 26, 2026latest review
Viagra Sildenafil: Regulatory History library
Showing 7 of 7 clinical reviews.
Viagra (Sildenafil) Compounding Legal Status: FDA Rules, Shortage Exemptions, and What Patients Need to Know
A clinical guide to the legal status of compounded sildenafil (Viagra), including FDA regulations, 503A and 503B exemptions, patent history, and what the current rules mean for patients and prescribers.
Viagra EMA vs FDA: How Two Regulators Shaped Sildenafil Access Worldwide
A side-by-side comparison of FDA and EMA regulatory approaches to Viagra (sildenafil), covering approval timelines, label differences, OTC reclassification, post-market safety surveillance, and what these divergent paths mean for prescribers and patients.
Viagra FAERS Safety Signals: What the FDA's Adverse Event Data Really Shows
How to interpret FDA adverse-event reports for Viagra and sildenafil, including the database's limits and the serious risks described in current prescribing information.
Viagra Global Regulatory Status: FDA Approval, International Classifications, and Post-Market Safety
A comprehensive review of sildenafil (Viagra) regulatory status worldwide, including FDA approval history, EMA authorization, OTC reclassification in the UK, and ongoing post-market surveillance data.
Viagra Legal and Patent Challenges: The Full Regulatory Timeline
A detailed look at every major legal battle, patent dispute, and regulatory milestone in sildenafil's history, from FDA approval in 1998 through generic entry and beyond.
Viagra Pipeline and Next-Gen Sildenafil: What the FDA Record Shows and What Comes Next
A clinical review of sildenafil's regulatory history, current FDA label, post-market safety data, and the next-generation PDE5 inhibitor pipeline for erectile dysfunction.